Laurie Barclay, MD Oct. 15, 2002
The U.S. Agency for Healthcare Research and Quality (AHRQ), a division of the Department of Health and Human Services, has assembled the evidence available on s-Adenosyl-L-Methionine (SAMe) and has shown actual benefit for the treatment of depression, osteoarthritis, and liver disease.
“The [AHRQ] report indicates that that this is a compound worthy of further investigation,” Maurizio Fava, MD, director of the depression clinic and research program at Massachusetts General Hospital in Boston, tells Medscape. “True, these are very small studies, but they consistently suggest the efficacy of this compound in depression.”
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!